

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 2, 2005

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-12957

22-2372868

(State or other jurisdiction (Commission File No.) (IRS Identification No.)
of incorporation)

685 Route 202/206, Bridgewater, New Jersey

08807

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (908) 541-8600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On September 6, 2005, Enzon Pharmaceuticals, Inc. ("Enzon") issued a press
release announcing the appointment of Ivan Horak, M.D. to the position of
Executive Vice President, Research and Development and Chief Scientific Officer.
A copy of Enzon's press release dated September 6, 2005 is attached as Exhibit
99.1 to this Current Report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No. Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 6, 2005

By: /s/ Craig A. Tooman

Craig A. Tooman
Executive Vice President, Finance
and Chief Financial Officer

Enzon Names Dr. Ivan Horak Chief Scientific Officer

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Sept. 6, 2005--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the appointment of Ivan Horak, M.D. to the position of Executive Vice President of Research and Development and Chief Scientific Officer. In his new position Dr. Horak will oversee all aspects of Enzon's research and development, regulatory affairs, and quality assurance activities.

Dr. Horak brings an impressive background in drug development to Enzon and is a board certified medical oncologist. He has held a number of senior medical and scientific positions in the pharmaceutical industry, as well as the National Cancer Institute (NCI).

"The addition of Dr. Horak to our executive management team further strengthens the pharmaceutical expertise at Enzon. Dr Horak will be instrumental in enhancing the productivity of our R&D pipeline," said Jeffrey H. Buchalter, Enzon's chairman and chief executive officer. "I have known Dr. Horak professionally for many years and have full confidence his continued leadership within the oncology community will contribute greatly to our long-term success in this therapeutic area."

Dr. Horak joins Enzon from Immunomedics, Inc. (Nasdaq: IMMU), where he served as Chief Scientific Officer since July 2003 and Executive Vice President of Research and Development since May 2002. Before joining Immunomedics, Dr. Horak was employed by Pharmacia as a Vice President for Clinical Oncology, where he helped direct the global development of oncology compounds from 1999 to 2002, including Camptosar(R) for metastatic colorectal cancer.

From 1996 to 1999, Dr. Horak held a variety of clinical research positions at Janssen Research Foundation, a subsidiary of the Johnson & Johnson Company, including International Director for Clinical Research and Development, Oncology.

Prior to joining Janssen, Dr. Horak spent nine years at the NCI where he most recently served as a cancer expert for the Metabolism Branch.

In addition to over 50 scientific publications, Dr. Horak is a member of several prominent medical societies and has served on various committees for the American Association for Cancer Research and the International Union Against Cancer. He also serves on the editorial board of the prestigious journal, Cancer Research.

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Further information about Enzon can be found on the Company's web site at www.enzon.com.

All information in this press release is as of September 6, 2005 and the Company undertakes no duty to update this information.

CONTACT: Enzon Pharmaceuticals, Inc.
Susan Mesco, 908-541-8678